Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “strong-buy” rating in a report issued on Thursday, Zacks reports.
Several other brokerages also recently weighed in on COLL. Needham & Company LLC lowered their price objective on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They issued a “buy” rating and a $49.00 target price on the stock. Oppenheimer initiated coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They set an “outperform” rating and a $50.00 price target for the company. Piper Sandler reiterated a “neutral” rating and set a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a report on Friday, August 7th. Finally, Weiss Ratings cut shares of Collegium Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $48.71.
Get Our Latest Stock Analysis on Collegium Pharmaceutical
Collegium Pharmaceutical Trading Up 0.0%
Shares of NASDAQ COLL traded up $0.01 during midday trading on Thursday, reaching $23.19. The company had a trading volume of 558,644 shares, compared to its average volume of 831,925. Collegium Pharmaceutical has a one year low of $21.43 and a one year high of $50.79. The company has a quick ratio of 0.84, a current ratio of 1.03 and a debt-to-equity ratio of 3.32. The firm’s fifty day moving average price is $24.07 and its 200-day moving average price is $30.84. The stock has a market cap of $755.07 million, a PE ratio of 18.70, a price-to-earnings-growth ratio of 0.72 and a beta of 0.73.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%. The company had revenue of $199.88 million during the quarter, compared to analysts’ expectations of $199.62 million. During the same period in the prior year, the business posted $1.68 EPS. Collegium Pharmaceutical’s quarterly revenue was up 6.3% compared to the same quarter last year. On average, equities research analysts anticipate that Collegium Pharmaceutical will post 6.42 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Farther Finance Advisors LLC raised its holdings in Collegium Pharmaceutical by 23.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 16,406 shares of the specialty pharmaceutical company’s stock worth $358,000 after purchasing an additional 3,082 shares in the last quarter. WINTON GROUP Ltd bought a new stake in shares of Collegium Pharmaceutical during the 2nd quarter valued at about $536,000. Squarepoint Ops LLC boosted its stake in shares of Collegium Pharmaceutical by 124.8% during the 2nd quarter. Squarepoint Ops LLC now owns 47,897 shares of the specialty pharmaceutical company’s stock valued at $1,734,000 after purchasing an additional 26,589 shares in the last quarter. Corient Private Wealth LP increased its position in shares of Collegium Pharmaceutical by 60.5% during the second quarter. Corient Private Wealth LP now owns 71,870 shares of the specialty pharmaceutical company’s stock valued at $2,603,000 after buying an additional 27,097 shares during the period. Finally, Amundi increased its position in shares of Collegium Pharmaceutical by 188.0% during the second quarter. Amundi now owns 23,492 shares of the specialty pharmaceutical company’s stock valued at $850,000 after buying an additional 15,336 shares during the period.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on developing, acquiring and commercializing medicines for central nervous system disorders. The company’s portfolio is concentrated in pain management and includes products for chronic and acute pain, opioid-induced constipation and related conditions.
Collegium’s marketed products include Xtampza ER, an extended-release oxycodone formulation designed with the company’s DETERx abuse-deterrent technology; Nucynta and Nucynta ER, tapentadol products for acute and chronic pain; Belbuca, a buprenorphine buccal film for chronic pain; and Symproic, a treatment for opioid-induced constipation.
Further Reading
- Five stocks we like better than Collegium Pharmaceutical
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
